Individual stock news: 1. Shell (SHEL.N) wins appeal in the latest emissions ruling in the Netherlands. 2. AstraZeneca (AZN.O) raises revenue and profit expectations for this year again. 3. Boeing (BA.N) secures an order for 80 737 Max aircraft from Avia Solutions Group. 4. According to the official website of CDE, Novartis (NVS.N)'s hydrochloride aqushentan tablets are planned to be included in priority review, indicated for proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 5. Johnson & Johnson (JNJ.N)'s nivolumab injection is planned to be included in priority review for the treatment of generalized myasthenia gravis in patients positive for anti-acetylcholine receptor antibodies. 6. Morgan Stanley raises the target price for Dell (DELL.N) from $136 to $154 and maintains an ‘overweight’ rating, citing increased sales of the company’s AI servers. 7. Tiger Brokers (TIGR.O) announces Q3 financial results with revenue of $101 million, a 15.6% QoQ rise and a 44.1% YoY rise, reaching a historical high; the non-GAAP net profit of the vesting parent company is $20.1 million, a 286.5% QoQ rise and a 25.6% YoY rise. 8. Huya (HUYA.N): Q3 total company revenue reached 1.54 billion yuan, with a vesting parent company net profit of 78 million yuan. Among them, revenue from game-related services, advertising, and other businesses rose by 209.3% YoY to 410 million yuan.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Jinshi data sorting: Daily US stock market news express (November 12, Tuesday)
Individual stock news: 1. Shell (SHEL.N) wins appeal in the latest emissions ruling in the Netherlands. 2. AstraZeneca (AZN.O) raises revenue and profit expectations for this year again. 3. Boeing (BA.N) secures an order for 80 737 Max aircraft from Avia Solutions Group. 4. According to the official website of CDE, Novartis (NVS.N)'s hydrochloride aqushentan tablets are planned to be included in priority review, indicated for proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 5. Johnson & Johnson (JNJ.N)'s nivolumab injection is planned to be included in priority review for the treatment of generalized myasthenia gravis in patients positive for anti-acetylcholine receptor antibodies. 6. Morgan Stanley raises the target price for Dell (DELL.N) from $136 to $154 and maintains an ‘overweight’ rating, citing increased sales of the company’s AI servers. 7. Tiger Brokers (TIGR.O) announces Q3 financial results with revenue of $101 million, a 15.6% QoQ rise and a 44.1% YoY rise, reaching a historical high; the non-GAAP net profit of the vesting parent company is $20.1 million, a 286.5% QoQ rise and a 25.6% YoY rise. 8. Huya (HUYA.N): Q3 total company revenue reached 1.54 billion yuan, with a vesting parent company net profit of 78 million yuan. Among them, revenue from game-related services, advertising, and other businesses rose by 209.3% YoY to 410 million yuan.